Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11938182
Halogenated xanthenes as vaccine adjuvants
granted -
US 11939343
Sting agonist compounds and methods of use
granted -
US 11938177
Peptide vaccine formulations and use thereof for inducing an immune response
granted -
US 11938174
Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
granted -
US 11938148
Treatment of neurodegenerative disease with sodium chlorite
granted -
US 11939363
Translatable molecules and synthesis thereof
granted -
US 11938147
Treatment of neurodegenerative disease with sodium chlorite
granted -
US 11938134
Metalloenzyme inhibitor compounds
granted -
US 11938124
Combination therapy for treatment of cancer
granted -
US 11939402
Antifungal peptides, compounds including the same, and methods of use thereof
granted -
US 11938149
Treatment of neurodegenerative disease with sodium chlorite
granted -
US 11939356
Self-assembling insect ferritin nanoparticles
granted -
US 11938101
Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
granted -
US 11939367
BTLA fusion protein agonists and uses thereof
granted -
US 11938171
Therapeutic systems, devices, and compositions with wound healing and tissue regenerative properties, uses thereof, and corresponding methods
granted -
US 11938125
Use of Hsp70 as a regulator of enzymatic activity
granted -
US 11939377
Affinity matured CD22-specific monoclonal antibody and uses thereof
granted -
US 11939361
Compositions of peptide inhibitors of Interleukin-23 receptor
granted -
US 11939604
Modified cascade ribonucleoproteins and uses thereof
granted -
WO 2024064327
OLIGOSACCHARIDES DE LAIT HUMAIN POUR AMÉLIORER LA FONCTION DE BARRIÈRE HÉMATO-ENCÉPHALIQUE
granted -
CA 3263063
VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)
granted -
US 11945855
Recombinant polypeptides comprising modified MHC class II DRa1 domains and methods of use
granted -
US 11946049
tRNA/pre-miRNA compositions and use in treating cancer
granted -
US 11945794
Nuclear transport modulators and uses thereof
granted -
US 11944683
Pharmaceutical compositions comprising meloxicam
granted -
US 11945795
Islet cell manufacturing compositions and methods of use
granted -
US 11945781
Compounds for the treatment of acute and chronic kidney disease
granted -
US 11944658
Methods of heat inactivation of adenovirus
granted -
US 11944656
Microbials for feed
granted -
US 11944627
Methods for treating hematological malignancies and Ewing's sarcoma
granted -
US 11944617
Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
granted -
US 11944644
T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof
granted -
US 11944626
Small molecule inhibitors of ALDH and uses thereof
granted -
US 11944679
Genome-wide identification of immune evasion functions in a virus
granted -
US 11944532
Engineered tendon graft for rotator cuff repair
granted -
US 11946065
Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB
granted -
US 11945822
Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase
granted -
US 11944687
Carbohydrate conjugate RNA agents and process for their preparation
granted -
US 11944618
Subcutaneous delivery of polymer conjugates of therapeutic agents
granted -
US 11945830
Antiviral heterocyclic compounds
granted -
US 11945872
Anti-ACVR1 antibodies and uses thereof
granted -
US 11944614
Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors
granted -
US 11944666
Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion protein
granted -
US 11945778
C4-carbonothioate-substituted tryptamine derivatives and methods of using
granted -
US 11945824
Heterocyclic compounds as anti-viral agents
granted -
WO 2024068265
PARTICULES DE TYPE VIRUS PRÉSENTANT DES ANTIGÈNES DU SARS-COV-2 UTILISÉES EN TANT QUE VACCINS DE RAPPEL ET LEURS UTILISATIONS
granted -
US 11952408
HPV-specific binding molecules
granted -
US 11952419
Reagents and methods for treating cancer and autoimmune disease
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.